Regulatory Approvals, Public Offerings and Clinical Trial Results - Research Report on Theravance, Synageva, Nektar, Clovis

 Regulatory Approvals, Public Offerings and Clinical Trial Results - Research
    Report on Theravance, Synageva, Nektar, Clovis Oncology, and ImmunoGen

PR Newswire

NEW YORK, October 7, 2013

NEW YORK, October 7, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Theravance
Inc. (NASDAQ: THRX), Synageva BioPharma Corp. (NASDAQ: GEVA), Nektar
Therapeutics (NASDAQ: NKTR), Clovis Oncology, Inc. (NASDAQ: CLVS), and
ImmunoGen, Inc. (NASDAQ: IMGN). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Theravance Inc. Research Report

On September 20, 2013, Theravance Inc. (Theravance) and GlaxoSmithKline plc
(GSK) announced that the Japanese Ministry of Health, Labour and Welfare has
approved RELVAR™ ELLIPTA™ for the treatment of bronchial asthma (in cases
where concurrent use of inhaled corticosteroid and long-acting inhaled beta[2]
agonist is required). "The approval of Relvar Ellipta will provide Japanese
physicians with a new, important once-daily, inhaled treatment option for
their asthma patients," said Rick E Winningham, CEO ofTheravance. "This first
approval of Relvar Ellipta in asthma represents yet another significant
milestone in the respiratory partnership between Theravance and GSK." The Full
Research Report on Theravance Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/fa70_THRX]

--

Synageva BioPharma Corp. Research Report

On September 30, 2013, Synageva BioPharma Corp. (Synageva) announced the
closing of a $179 million underwritten public offering of 3.2 million shares
of common stock. The Company informed that this offering included 412,500
shares of common stock that were issued pursuant to the exercise of the
underwriters' option to purchase additional shares, at a price of $56.63 per
share. The Full Research Report on Synageva BioPharma Corp. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/8624_GEVA]

--

Nektar Therapeutics Research Report

On September 30, 2013, Nektar Therapeutics (Nektar) reported that its partner
AstraZeneca has announced that the European Medicines Agency (EMA) has
accepted the Marketing Authorisation Application for Naloxegol. Nektar
informed that Naloxegol is an investigational peripherally-acting mu-opioid
receptor antagonist designed for the treatment of opioid-induced constipation
(OIC) for adult patients 18 years and older, including patients with
inadequate response to laxatives. The Company claims that Naloxegol has the
potential to be the first once-daily oral peripherally-acting mu-opioid
receptor antagonist medication for patients with OIC and was developed using
Nektar's oral small molecule polymer conjugate technology. The Full Research
Report on Nektar Therapeutics - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/3421_NKTR]

--

Clovis Oncology, Inc. Research Report

On September 29, 2013, Clovis Oncology, Inc. (Clovis Oncology) announced
updated results from an ongoing Phase I/II monotherapy study of rucaparib, the
Company's oral, potent, small molecule poly (ADP-ribose) polymerase (PARP)
inhibitor being developed for the treatment of ovarian cancer. Dr. Rebecca
Kristeleit, Clinical Senior Lecturer and Consultant Medical Oncologist UCLH
and UCL Cancer Institute in London, said, "We've seen significant clinical
activity with one complete response in breast cancer and six partial responses
in ovarian, breast and pancreatic cancers to date, and a disease control rate
in patients with germline BRCA mutant ovarian (platinum-sensitive and
platinum-resistant) cancer of 100% and 63% at 12 and 24 weeks, respectively. I
am pleased to be participating in the Phase II and pivotal Phase III trials
(ARIEL2 and ARIEL3) which aim to build on the clear activity of rucaparib in
BRCA-mutant ovarian cancer and prospectively identify and test other genetic
mutations associated with sensitivity to PARP inhibition in ovarian cancer.
This approach has the potential to broaden applicability of PARP inhibitor
treatment for ovarian cancer as well as other solid tumors and hopefully
benefit many patients." The Full Research Report on Clovis Oncology, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/6a2a_CLVS]

--

ImmunoGen Inc. Research Report

On September 20, 2013, ImmunoGen, Inc. (ImmunoGen) announced positive
regulatory decisions for Kadcyla (trastuzumab emtansine, formerly T-DM1) in
both the European Union (EU) and Japan, the two largest pharmaceutical markets
after the US. Kadcyla was approved for marketing in the US earlier in 2013.
The EU's Committee for Medicinal Products for Human Use has recommended
approval of Kadcyla for the treatment of adults with HER2-positive, inoperable
locally advanced or metastatic breast cancer who previously received
trastuzumab and a taxane, separately or in combination. Further, the Japanese
Ministry of Health, Labor and Welfare has approved Kadcyla for the treatment
of inoperable or recurrent HER2-positive breast cancer based on results from a
Japanese Phase II trial and the EMILIA Phase III trial. The Full Research
Report on ImmunoGen Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/11c8_IMGN]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)